Navigation Links
Adventrx Announces Positive Data From Multidrug Therapy With,CoFactor

ly significantly less (p < 0.05) than mice treated with either capecitabine alone (461.0 mm3 +/- 50.4) or mice treated with LV, 5-FU and capecitabine (447.8 mm3 +/- 46.5). Consistent with superior inhibition of tumor growth, treatment with CoFactor, 5-FU and capecitabine also prolonged survival compared to the other treatment regimens. The median survival of CoFactor, 5-FU and capecitabine treated mice (60 days) was statistically significantly longer (p < 0.05) than capecitabine alone (38 days) and LV, 5-FU and capecitabine (39 days). Importantly, the increased tumor inhibition and survival benefits of treatment with CoFactor, 5-FU and capecitabine did not come at the cost of added toxicity. Treatment with CoFactor, 5-FU and capecitabine caused less severe weight loss than all other drug treatments, including capecitabine alone. These results suggest a hybrid treatment regimen, consisting of a CoFactor and 5-FU treatment backbone coupled with capecitabine, might confer improvements in antitumor activity and survival without corresponding increases in systemic toxicity in patients with colorectal cancer. The Company plans to pursue further testing of this CoFactor treatment regimen.

About CoFactor

CoFactor (ANX-510) is a folate-based biomodulator drug designed to replace leucovorin as the preferred method to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy 5-fluorouracil (5-FU). In comparison to leucovorin, CoFactor creates more stable binding of the active form of 5-FU to the target enzyme, thymidylate synthase (TS). CoFactor bypasses the metabolic pathway required by leucovorin to deliver the active form of folate, allowing 5-FU to work more effectively. CoFactor is in Phase 3 and Phase 2b clinical trials for the treatment of metastatic colorectal cancer, as well as in a Phase 2 clinical trial for the treatment of advanced breast cancer.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:8/29/2014)... 29, 2014   Mast Therapeutics, Inc. ... today that Santosh Vetticaden, Chief Medical Officer and ... for personal reasons, in mid-September.  Edwin L. ... Aires Pharmaceuticals, which Mast acquired earlier this year, ... Company,s interim Chief Medical Officer.  Dr. Parsley previously ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
(Date:8/29/2014)... 2014 Does your doctor know what you,re smoking?  ... recommended marijuana to the over 112,000 currently registered patients under ... of the other roughly 20,300+ active physicians listed with the ... it – even though a poll in February 2014 showed ... have tried it. "With marijuana legalization underway, ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... 10, 2011 MAQUET Cardiovascular, a leading provider ... signed a three-year, dual-source contract with Premier Healthcare ... the Premier membership.  The contract includes the CS300 ... 50cc IABP Catheter, SENSATION® 7Fr. IABP Catheter and ...
... PRINCETON, N.J., Oct. 10, 2011 Pharmasset, Inc. (Nasdaq: ... two treatment arms to the ELECTRON trial of PSI-7977, ... chronic hepatitis C (HCV). The rapid and consistent antiviral ... to date provided the rationale for additional exploratory regimens ...
Cached Medicine Technology:MAQUET Cardiovascular Awarded Three-Year Contract From Premier Healthcare Alliance for Intra-Aortic Balloon Pumps 2MAQUET Cardiovascular Awarded Three-Year Contract From Premier Healthcare Alliance for Intra-Aortic Balloon Pumps 3Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C 2Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C 3Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C 4
(Date:8/30/2014)... Saturday 30 August 2014: A new method ... external defibrillators (AEDs) was presented at ESC Congress today ... predictive method, Paris needs 350 AEDs located in public ... arrest (OHCA). , Dr Dahan said: "Out of hospital ... an annual incidence ranging between 50 and 100 per ...
(Date:8/30/2014)... Colorado (PRWEB) August 31, 2014 According to ... proven step by step holistic system for skin health. It ... has already been tried by more than 138,000 patients from ... by Mike Walden, who says that this method will not ... permanent clear skin. , What makes this program unique ...
(Date:8/30/2014)... 2014 Zensah®, the leader in compression technology ... emerge as a best-seller within golf and tennis. Golfers and ... they enjoy most by using the compression elbow sleeve to ... is a condition that causes pain on the inner side ... attach to the bony bump on the inside of your ...
(Date:8/30/2014)... The Truth about Six Pack Abs is a new method ... shocking foods that can burn belly fat, unique workouts that ... as some motivation secrets for successful fitness. , The author ... trick that can help users reduce junk-food cravings. , ... think, cardio exercise routines are not the best to be ...
(Date:8/30/2014)... 2014 Information supplied by insurance companies ... better prices to consumers in 2014. A group of ... when using the open system for adults at ... to use this year can help the average person ... location and not from medical histories. The finder tool ...
Breaking Medicine News(10 mins):Health News:New method predicts optimal number and location of AEDs 2Health News:Acne No More Review Reveals Unusual Tip to Eliminate Acne Permanently 2Health News:Relieve Golfers and Tennis Elbow Pain with the Zensah® Compression Elbow Sleeve 2Health News:Truth about Six Pack Abs Review Reveals Unique Method to Eliminate Stubborn Stomach Fat 2Health News:Term Life Insurance Rates Now Found Nationally by New Insurer Finder Tool 2
... 6 In a newly-published special supplement, the Journal ... prevent and treat venous thromboembolism (VTE), a major cause ... Lippincott Williams & Wilkins (LWW) is publishing ... that includes both the common medical condition of deep ...
... statement in observance of Pancreatic Cancer Awareness Month , WASHINGTON, ... yet it is the fourth leading cause of death by cancer ... be diagnosed with the disease and more than 35,000 will die ... find a cure for pancreatic cancer researchers have to know more ...
... role in boosting memories -- or forgetting them, researchers say ... remember the first time you smelled a type of flower? ... brain might. , In the study, published online Nov. ... objects to adult study participants. They paired the objects with ...
... small group of patients with severe Graves, eye disease ... vision following treatment with the drug rituximab. Inflammation ... were significantly reduced. The same patients had not previously ... disease. Raymond S. Douglas, M.D., Ph.D., an oculoplastics ...
... TORONTO, On November 6, 2009 Researchers at St. ... fire services across Ontario found that a bystander who attempts ... 50 per cent. But Dr. Laurie Morrison and the research ... per cent of bystanders in Toronto are willing to help, ...
... , COLUMBUS, Ohio, Nov. 6 The Ohio Association of ... health care premiums and less robust benefits if proposals being ... were to become law. , If the reforms proposed by ... in Ohio would increase 60% over five years in the ...
Cached Medicine News:Health News:Journal of Cardiovascular Nursing Urges Policies and Prevention To Reduce Deaths from Venous Thromboembolism 2Health News:Journal of Cardiovascular Nursing Urges Policies and Prevention To Reduce Deaths from Venous Thromboembolism 3Health News:New Smells 'Etched' in Brain: Study 2Health News:Researchers find new way to attack inflammation in Graves' eye disease 2Health News:Less than 1 in 3 Toronto bystanders who witness a cardiac arrest try to help: Study 2Health News:Less than 1 in 3 Toronto bystanders who witness a cardiac arrest try to help: Study 3Health News:Congressional Health Care Reform Proposals Will Make Health Care More Expensive, Less Robust for Ohioans 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: